TAT meetings are characterized by their focus on targeted cancer therapeutics, in particular the most promising ones in the late preclinical and early clinical development stages. TAT 2012 will offer excellent opportunities for the presentation and discussion of ongoing and completed phase 1 studies in a highly interactive setting. Apart from being of importance to everyone involved in anticancer drug development on a daily basis, the TAT 2012 program will be of high educational value to oncologists wishing to stay abreast of emerging new treatment options.

Distinguishing features of TAT 2012:
Focused on early phase development of promising targeted agents for cancer therapy
Medium-sized event, creating excellent possibilities for personal interactions with colleagues
Participants from academia and industry
No parallel sessions, avoiding the need to make difficult choices
Attention to methodological and regulatory issues in new drug development
Ample opportunity to present your own work in front of an international expert audience